Clinical Trial Update: Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biomarkers of response to the combination of ipilimumab and nivolumab as first-line therapy for non-small cell lung cancer has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-08-22